Drug Trial Radar · NCT00311870
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
Last checked: Nov 19, 2026Latest source record: Apr 6, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Mar 1993
Primary completion
Not stated
Study completion Apr 1999
Sponsor
- Lead sponsor
- Steno Diabetes Center CopenhagenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bayer
- First posted
- Apr 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months
Conditions
- Diabetic Nephropathy
Interventions
nisoldipineDrug
lisinoprilDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in glomerular filtration rate from study start to study end
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Steno Diabetes Center
Gentofte Municipality, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.